Metabolic Disorder

The benefits of umbilical cord-derived MSCs as a cell source 1:11
The benefits of umbilical cord-derived MSCs as a cell source
Mathias Svahn • 6 Oct 2021
MSCs for type I diabetes 1:20
MSCs for type I diabetes
Lindsay Davies • 7 Jun 2021
ProTrans: Wharton’s jelly-derived MSC therapy for type I diabetes 2:13
ProTrans: Wharton’s jelly-derived MSC therapy for type I diabetes
Lindsay Davies • 7 Jun 2021
Developing the bioartificial pancreas 5:13
Developing the bioartificial pancreas
Ekaterine Berishvili • 1 Jun 2021
Tackling remaining obstacles to cell therapy for type I diabetes 3:54
Tackling remaining obstacles to cell therapy for type I diabetes
Ekaterine Berishvili • 1 Jun 2021
Enhancing AAV gene therapy in children with inborn errors of metabolism 2:25
Enhancing AAV gene therapy in children with inborn errors of metabolism
Gloria Gonzalez-Aseguinolaza • 18 May 2021
Vector-based therapies for metabolic disorders 3:09
Vector-based therapies for metabolic disorders
Gloria Gonzalez-Aseguinolaza • 18 May 2021
Neuraminidase could improve AAV9 gene therapy for Batten disease 1:45
Neuraminidase could improve AAV9 gene therapy for Batten disease
Kathrin Meyer • 18 May 2021
The future of cell-based therapies for type 1 diabetes 2:52
The future of cell-based therapies for type 1 diabetes
Ekaterine Berishvili • 1 Jun 2021
CTNS-RD-04: HSC gene therapy for cystinosis 7:49
CTNS-RD-04: HSC gene therapy for cystinosis
Stephanie Cherqui • 17 May 2021
AVR-RD-01: ex vivo lentiviral gene therapy for Fabry disease 3:52
AVR-RD-01: ex vivo lentiviral gene therapy for Fabry disease
Mark Thomas • 11 May 2021
The content of VJRegenMed is intended for healthcare professionals